Summary: Traumatic brain injury (TBI) is the leading cause of morbidity and mortality among children and both clinical and experimental data reveal that the immature brain is unique in its response and vulnerability to TBI compared to the adult brain. Current therapies for pediatric TBI focus on physiologic derangements and are based primarily on adult data. However, it is now evident that secondary biochemical perturbations play an important role in the pathobiology of pediatric TBI and may provide specific therapeutic targets for the treatment of the head-injured child. In this review, we discuss three specific components of the secondary pathogenesis of pediatric TBIinflammation, oxidative injury, and iron-induced damage -and potential therapeutic strategies associated with each. The inflammatory response in the immature brain is more robust than in the adult and characterized by greater disruption of the blood-brain barrier and elaboration of cytokines. The immature brain also has a muted response to oxidative stress compared to the adult due to inadequate expression of certain antioxidant molecules. In addition, the developing brain is less able to detoxify free iron after TBI-induced hemorrhage and cell death. These processes thus provide potential therapeutic targets that may be tailored to pediatric TBI, including anti-inflammatory agents such as minocycline, antioxidants such as glutathione peroxidase, and the iron chelator deferoxamine.
INTRODUCTION
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality among children and adolescents. In the United States alone, there are an estimated 475,000 annual cases of TBI among children under the age of 15 years, resulting in 2,685 deaths. 1 The disabilities resulting from pediatric TBI are often profound and life-long, 2 and include sensorimotor 3 and cognitive impairments 4 as well as psychological dysfunction. 4 TBI is defined as any head injury with traumatic etiology, including blunt or penetrating trauma and nonaccidental injury. Falls, motor vehicle accidents, and abuse account for the majority of injuries in children under four years of age, while motor vehicle accidents are most common among older children. 5 The primary injury may manifest as diffuse axonal injury, intraparenchymal contusions, intracranial hematomas, skull fractures, and combinations thereof. 6 This mechanical injury is often followed by secondary physiologic and biochemical derangements that generate further damage.
Pediatric versus adult TBI. Although there are similarities between head injury in the developing and adult brains, pediatric brain injury poses unique challenges. In general, the primary injury is more often diffuse in the child due to a greater head-to-torso ratio and brain-water content.
2 Clinical 2,7,8 and experimental 9 studies demonstrate that the developing brain may also be more vulnerable to traumatic injury than the adult brain. Such vulnerability mandates that the head-injured child must be viewed and treated differently than the head-injured adult.
10
Age-dependent variation. Adding to this challenge is the considerable age-dependent variation that exists within the pediatric population. The developmental processes of myelination, 11 neuronal pruning, 12 axonal growth, 13 and synaptic reorganization 12 may continue for years after birth. Standard physiologic measurements such as intracranial pressure, mean arterial pressure, and cerebral perfusion pressure also vary with age. 10, 14 For these reasons, it is perhaps not surprising that the developing brain exhibits age-dependent vulnerability to TBI, with children under four years of age showing the greatest vulnerability as evidenced by more profound cognitive and motor deficits.
15
Current acute management of severe pediatric TBI. Management of the head-injured child aims to avoid, anticipate, and actively treat secondary brain insults. Adelson et al. 10 have recently published evidencebased guidelines that establish what is known about the acute management of pediatric TBI ranging from trauma systems and pre-hospital management to measurement and manipulation of physiologic variables, nutritional support, and prophylaxis of seizures. These guidelines provide a unified basis from which physicians can make management decisions. They also serve as a foundation from which to direct future research, thus facilitating the advancement of the field of pediatric neurotrauma.
Determinants of recovery
Recovery is determined by the magnitude of the primary mechanical insult, characterized by shearing and tearing of neural and vascular structures, and by physiologic and biochemical pathogenic events that progressively compromise otherwise intact tissue. Physiologic events associated with TBI, including hypotension, 16 hypoxia, 16 hyperthermia (Ͼ38.5°C), 17 elevated intracranial pressure, 10 and posttraumatic seizures, 10 adversely affect outcome in brain-injured children. Biochemical perturbations associated with inflammation, oxidative stress, toxic metabolites, excitotoxicity, and apoptosis may likewise impair brain function. 18, 19 The challenge in advancing the field of pediatric neurotrauma will be to develop therapies that are specifically tailored to the maturational state of the brain. In that context, secondary pathogenic events are a promising target of current novel therapies and research. In this review, we focus on three major secondary events that likely influence outcome after brain injury -inflammation, oxidative injury, and iron-mediated damage -and we consider potential therapeutic interventions in the context of each of these events.
Inflammation and brain injury
There is growing evidence that inflammation is critical to both secondary injury and repair mechanisms in the central nervous system. Here we consider the complex interplay between inflammatory events and early secondary pathogenesis.
Characterization of inflammation.
The hallmarks of early inflammation in the brain include activated microglia, the presence of neutrophils, and edema. Microglia act as immune reactive surveillance cells and are integral to the detection of pathogens, host defense, and tissue repair. 20 Of the variety of cytotoxic factors released by microglia, reactive oxygen species such as the superoxide free radical are thought to play a role in inflammation-mediated damage to neurons. 21 Neutrophils can likewise promote early pathogenesis, including brain swelling, 22 through the release of free radicals, proteases, and proinflammatory cytokines.
23-25
Modulators of early inflammation. An acute inflammatory response, which involves the integrated activities of cytokines, chemokines, and vascular adhesion molecules, contributes to the pathophysiology of TBI including vascular dysfunction and cell injury. 26 -28 Cytokines are multifunctional peptides that act as pro-inflammatory molecules. Many cytokines, including NF-B, TNF-␣, IL-1␤, IL-6, and IL-10, are induced in response to TBI.
26,27,29 -35 Bell et al. 36 measured IL-6 in the cerebrospinal fluid of infants and children with severe TBI and found a 60-fold increase over controls. This level was similar to that seen in the serum of infants and children with septic shock, 37 demonstrating the magnitude of inflammation in the injured immature brain. Although these cytokines are implicated in early pathogenesis, there is increasing evidence for more complex roles in neuronal injury and survival that may depend upon their concentrations as well as the timing of their expression after injury.
27
Chemokines are known for their roles in leukocyte communication and migration. 38 They comprise a family of structurally related cytokines that activate and direct leukocyte traffic. 38 Interleukin-8 (IL-8), a chemokine in humans, modulates chemotaxis of neutrophils. Several lines of evidence implicate IL-8 as a mediator of inflammation in the injured brain. Direct injection of IL-8 into the murine brain results in marked neutrophil recruitment, coincident with disruption of the blood-brain barrier. 39 Moreover, clinical studies have demonstrated a significant elevation of IL-8 in the cerebrospinal fluid of severely brain-injured children. Adhesion molecules are integral to leukocyte transmigration, a process that involves the binding of selectins, which are expressed on activated endothelium, to ligands present on leukocytes. 43 This binding promotes leukocytic rolling with subsequent attachment to intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1), which are present on the endothelium. This attachment is a necessary first step in the transmigration of leukocytes across the endothelial cell. Both ICAM-1 and VCAM-1 are upregulated in the traumatized adult brain. 44 -46 Moreover, there is a correlation between elevated levels of ICAM-1, severity of injury, and neurologic outcome in clinical studies of head injury in children.
47
Inflammation and the developing brain: "Window of susceptibility". The kinetics of leukocyte recruitment during acute inflammation vary according to age. Adult mice are more resistant to inflammation than are one to three week old mice, as evidenced by less leukocyte recruitment and barrier disruption in response to cytokines. 48, 49 The biologic basis for this age-related "window of susceptibility" is not clear. There is evidence that marked neutrophil infiltration and barrier disruption seen in the young brain may reflect increased susceptibility to the neutrophil chemoattractive effects of chemokines.
50
Inflammation as a target for therapeutic intervention. With inflammation playing such an important role in the pathophysiology of TBI, it is a logical step to consider anti-inflammatory agents as potential therapies for TBI (Table 1) . We focus here on minocycline, a tetracycline derivative, because of its broad application to various models of brain injury. Minocycline has generated much interest as a modifier of acute and chronic neuroinflammation and for its ability to reduce neuronal apoptosis. The drug was originally found to attenuate the delayed phase of injury after transient cerebral ischemia by reducing microglial activation and proliferation. 51, 52 Minocycline likewise modulates neuroinflammation in animal models of multiple sclerosis, 53 Huntington's disease, 54 and amyotrophic lateral sclerosis. 55 Its action is exerted at least in part through inhibition of mitogenactivated protein kinase p38, a stress-activated protein kinase that mediates the production of other inflammatory mediators. 56 The beneficial effects of minocycline are not limited to its ability to reduce inflammation, however. Minocycline also targets neuronal apoptosis by inhibiting caspase-1 57 and caspase-3.
58
As with the adult brain, minocycline protects against injury in the immature brain. 58 However, unlike in the adult, this protection is not sustained over time. 59 Such findings serve to emphasize the unique response of the developing brain to injury and remind us that the neuroprotective effects of a particular drug in the injured adult brain may not be predictive of its action in the immature brain. Any potential therapeutic agent must therefore be carefully evaluated in this context. Furthermore, minocycline is known to cause tooth discoloration and affect bone growth in young children, demonstrating that any potential therapeutic agent may have adverse developmental effects. This collective experience with minocycline highlights an important point; screening of candidate anti-inflammatory agents should be done in ageappropriate models of injury with the understanding that their actions may vary according to the nature of the injury and the molecular specificity of their targets. 
Oxidative damage
Oxidative damage is a significant component of the secondary injury cascade that accompanies TBI ( Figure  1 ). 60 -64 Such injury is mediated by reactive oxygen and nitrogen species, including the superoxide ion, hydrogen peroxide, hydroxyl radical, nitric oxide, and peroxynitrite, 61, 63, 65 Glutamate-mediated excitotoxicity, which leads to an increase in intracellular calcium, induces several endogenous enzymes that produce free radicals, including nitric oxide synthase, xanthine oxidase, and the phospholipase A 2 -cyclooxygenase pathway. 63 Such changes in intracellular calcium also perturb mitochondrial function, leading to leakage of superoxide. 63, 66 The release of free iron, as discussed in the following section, is likewise an important component of the oxidative damage cascade, catalyzing the formation of superoxide from free oxygen and the potent hydroxyl radical from hydrogen peroxide. 61 Activated neutrophils can also directly produce superoxide 63 and nitric oxide. 61, 67 Finally, free radicals react with one another to produce additional free radicals such as peroxynitrite, which is generated from the reaction between superoxide and nitric oxide. 61 Several endogenous antioxidant compounds exist that prevent oxidative damage under physiologic conditions (Figure 1 ). Superoxide dismutase (SOD) catalyzes the conversion of superoxide to hydrogen peroxide. Glutathione peroxidase (GPx) and catalase then clear hydrogen peroxide, forming molecular oxygen and water. Free radical scavengers, collectively known as low molecular weight antioxidants, are also found in the brain. These include the endogenous molecules glutathione, melatonin, uric acid, and histidine-related compounds as well as exogenous molecules such as tocopherols (vitamin E), ascorbic acid, and lipoic acid, which are obtained from the diet. 64 After TBI, these antioxidant defense mechanisms can become overwhelmed, leading to cellular damage and death via free radical-mediated lipid peroxidation and protein and DNA oxidation.
61,63,65,68 The brain is especially susceptible to such oxidative damage due to its high fatty acid content and proportionately large share of total body oxygen consumption. 69 This vulnerability is further compounded in the immature brain by a reduced antioxidant reserve. Bayir et al. 70 assessed measures of oxidative stress and total antioxidant reserve in the cerebrospinal fluid of head-injured infants and children and demonstrated a reduction in total antioxidant reserve compared to controls as well as a depletion of the antioxidant compounds ascorbic acid and glutathione. Such findings may be due to the regulation of antioxidant enzymes during brain development and maturation. 71 For example, metallothioneins, compounds that act as both free radical scavengers and metal chelators, are expressed at lower levels in the immature brain than in the adult and their level of expression inversely correlates with neuronal degeneration after cortical ablation injury. 72 Similarly, certain SOD isoforms are known to be expressed at lower levels in the immature brain. 73 Superoxide dismutase. Three human isoforms of SOD exist. Copper-zinc SOD (SOD1) is predominately located within the cytosol and lysosomes of cells and is perhaps the most studied of the SOD isoforms in brain injury. Increased activity of SOD1 is associated with neuroprotection in the injured, adult brain. This is best exemplified in transgenic mice that overexpress SOD1, where there is reduced cerebral edema, tissue necrosis, and disruption of the blood-brain barrier along with an improvement in functional recovery after TBI as compared to wildtype controls. 74, 75 Similar neuroprotection is seen in these adult transgenic mice when subjected to focal ischemic brain injury. 76 Despite these findings, there is currently no evidence that SOD1 overexpression confers neuroprotection in the immature brain after TBI. In fact, at least in experimental models of neonatal hypoxia/ischemia, SOD1 overexpression exacerbates injury. 77 This adverse response has been attributed to These two molecules combine to form peroxynitrite, which leads to the production of multiple damaging free radicals, including nitrogen dioxide (NO 2 • ), the carbonate radical (CO 3 •-), and the hydroxyl radical (OH • ). Superoxide is also converted to hydrogen peroxide by the enzyme superoxide dismutase. Under normal physiologic conditions, hydrogen peroxidase is cleared by the enzymes catalase and glutathione peroxidase, which convert it to water and oxygen. In the presence of free iron, however, hydrogen peroxide can be metabolized to the hydroxyl radical. Together, these TBI-induced free radicals lead to oxidative damage and secondary brain injury. COX ϭ cyclooxygenase; GSH ϭ glutathione; GSSG ϭ glutathione disulfide.
inadequate antioxidant reserves in the immature brain leading to an accumulation of hydrogen peroxide. 78 Hydrogen peroxide itself is especially toxic to immature neurons 79 and in the presence of free metals, can be further metabolized to the hydroxyl radical. GPx and catalase limit this toxicity by catalyzing the reduction of hydrogen peroxide to water. The efficacy of superoxide dismutase is thus dependent upon these two downstream antioxidants to eliminate hydrogen peroxide.
A second SOD isoform, manganese SOD (SOD2), is most prevalent within mitochondria. Mice deficient in SOD2 show an increased release of mitochondrial cytochrome c after TBI that is associated with greater necrotic cell death within the cortical lesion. 80 Extracellular SOD (SOD3), the third SOD isoform, has not been studied in TBI. However, its overexpression has been shown to be beneficial in models of cerebral ischemia, 81, 82 while mice deficient in this enzyme are more vulnerable to ischemic injury. 83 Pharmacologic variants of SOD have also shown some efficacy in experimental models of TBI. These variants have been generated to increase the blood brain barrier permeability of SOD and thus improve its efficacy. Polyethylene glycol-conjugated SOD (PEG-SOD, pegorgotein) has been shown to improve post-injury motor deficits, but has no effect on balance or spatial memory deficits. 84 Another variant, lecithinized SOD, decreases edema and improves survival. 85 Interestingly, while PEG-SOD showed no effect on cognitive function, lecithinized SOD decreases neuronal loss in the hippocampal CA3 region, 86 which is associated with spatial memory.
87
Glutathione peroxidase. GPx is likely more important than catalase in eliminating hydrogen peroxide and in contributing to the increased vulnerability of the immature brain to injury. GPx activity in the brain is sevenfold higher than that of catalase 88 and its expression is more ubiquitous. 65 Although GPx is upregulated in the adult brain after TBI, no such upregulation occurs in the immature brain. 89 Similarly, GPx expression actually decreases in the neonatal brain after hypoxia/ischemia while catalase activity remains unchanged. 78 This inability of the immature brain to respond to injury by upregulating GPx may therefore play a role in the vulnerability of the immature brain to injury. In addition, overexpression of GPx in a model of hypoxia/ischemia improves outcome, 71 suggesting that this antioxidant enzyme has great promise as a potential therapeutic agent for pediatric TBI.
Other antioxidant compounds. Although a thorough discussion is beyond the scope of this review, many other agents with antioxidant properties have been studied and shown benefits in models of TBI. 64 106, 107 Multiple other novel antioxidants also exist. 108 -111 Unfortunately, only one of these promising compounds, melatonin, has been tested in a model of TBI in the immature brain, where it attenuates hippocampal neuronal cell death and improves spatial memory function.
105
Human studies. Despite such compelling experimental evidence, clinical trials using antioxidants in TBI have been less successful. A phase II clinical trial in which PEG-SOD was administered intravenously to adults within twelve hours after severe head injury demonstrated an improvement in three-and six-month mortality and functional outcome (as measured by the Glasgow Outcome Scale) in patients receiving the highest dose of PEG-SOD (10,000U/kg). 112 However, when further tested in a phase III randomized controlled trial, no statistical difference in mortality or outcome at three months post-injury was found between controls and patients receiving either 10,000U/kg or 20,000U/kg of PEG-SOD. 113 The free radical scavenger tirilazad mesylate also failed to show any benefit over placebo in a randomized controlled trial of adults with severe and moderate TBI with the exception of males presenting with a subarachnoid hemorrhage. 114 In this group, tirilazad mesylate treatment significantly reduced mortality at six months post-injury. Dexanabinol, a synthetic cannabinoid with antioxidant, anti-inflammatory, and antiglutamatergic properties, has also undergone phase II testing in severe TBI patients. 115 Patients receiving this drug showed improvements in initial intracranial pressure, cerebral perfusion pressure, and systolic blood pressure, with a trend towards improved six-month outcome. These results have led to a phase III trial that is currently ongoing. Unfortunately, no clinical trials have been conducted in head-injured children, in whom experimental data suggest antioxidant therapies may have the greatest effects.
Interestingly, ebselen, an antioxidant compound with properties that mimic GPx, has been tested clinically in adult patients with both ischemic and hemorrhagic stroke. 116 -118 In a randomized controlled trial of patients with ischemic stroke, those who received ebselen treatment within 24 hours after their stroke had significantly better functional outcomes one month later. 116 Similarly, in a randomized controlled study of patients with aneurysmal subarachnoid hemorrhage, ebselen treatment led to improved functional outcomes at three months in patients diagnosed with delayed ischemic neurologic deficits. 117 A third randomized controlled trial of patients with complete occlusion of the middle cerebral artery also showed benefits from ebselen treatment. 118 With such clinical successes in addition to laboratory evidence suggesting that GPx is a vital factor in the vulnerability of the immature brain to TBI, ebselen should be strongly considered as a potential therapy in pediatric TBI.
Iron accumulation in the injured brain
Degradation products of heme, and in particular free iron, are important sources of oxidative stress in the traumatized brain. 119 Iron reacts with hydrogen peroxide to form hydroxyl radicals ( Figure 1 ) and with lipids to generate alkoxy and peroxy radicals. As discussed in the previous section, the immature brain may be especially vulnerable to the adverse effects of oxidative stress, making iron a potential target for therapy after trauma to the immature brain.
Iron regulation during normal development. Iron and its regulatory proteins play a critical role in development and are likely important in defining the selective vulnerability of the developing brain to traumatic injury. Iron is necessary for growth and cellular differentiation due to its role as a constituent of molecules generating mitochondrial energy, such as cytochrome c. 120 Iron regulation is partly governed by transferrin, a transport protein, and ferritin, a storage protein. 120 These two molecules bind iron when it is not a component of ironcontaining moieties such as hemoglobin, myoglobin, and cytochrome molecules. Transferrin and ferritin are thus important in limiting the cytotoxic effects of iron. The concentrations of these binding proteins change throughout early development before reaching adult levels. 121 Such age-dependent variation may be a determinant of cellular vulnerability to iron accumulation. Free iron is found in the plasma of normal term and preterm neonates, indicating that the binding capacity of transferrin is saturated in the immature brain. [122] [123] [124] This coincides with a low concentration of transferrin in the cerebrospinal fluid of these children.
124
Iron accumulation after injury to the developing brain. Iron accumulates in the developing brain after TBI 119 ( Figure 2 ). However, it is unclear how such accumulation may modulate pathogenesis. Findings in models of hypoxia/ischemia may offer important insight into the heightened vulnerability of the immature brain to traumatic injury. There is increased iron deposition in subcortical regions and white matter of children with severe ischemia. 125 Similarly, there is excess iron deposition after experimental hypoxia/ischemia in the immature rodent. 126 The magnitude of iron accumulation is likely age-dependent. Iron rapidly accumulates in the immature brain after hypoxia/ischemia 127 in contrast to a more delayed accumulation in the adult brain.
128
Damaging effects of iron. Exposure of the neonatal brain to abnormally high levels of iron leads to cognitive and motor deficits manifested in adulthood.
129 On a cellular level, iron relocalizes from microglia to oligodendrocytes during normal maturation. 130 Furthermore, after hypoxia/ischemia, the localization of iron reverts to microglia. The sequestration of iron by microglia may therefore limit its availability to oligodendrocytes, resulting in impaired myelination. 126 This change in iron localization is possibly due to the fact that ferritin expression is delayed in oligodendrocytes in the injured immature brain.
126,131
Iron chelation -a possible therapy? Pharmacologic approaches to chelate iron have been important in understanding its pathogenicity after TBI. Several iron chelators have been investigated, including those that target either intracellular free iron, extracellular free iron, or both. 132 In a cold-induced model of brain injury, 2,3-dihydroxybenzoic acid, an extracellular ferric iron chelator, 2,2-bipyridine, an intracellular ferrous iron chelator, and deferoxamine, an intracellular and extracellular ferric iron chelator, were evaluated for their roles in brain edema and blood brain barrier disruption. 132 Only the 2,2-bipyridine-and deferoxamine-treated groups demonstrated significantly reduced edema and blood-brain barrier disruption. Deferoxamine is the most widely investigated iron-chelator in the setting of brain injury and it offers neuroprotection through multiple mechanisms. Deferoxamine scavenges ferric iron as well as the hydroxyl radical and the peroxynitrite anion. It attenuates oxidative stress in cultured neurons and astrocytes, likely a result of reducing the amount of iron available to generate free radicals. 133 It may also confer added protection to the injured immature brain by upregulating hypoxia-inducible factor-1, which promotes cell survival via the activation of molecules such as erythropoetin and vascular endothelial growth factor. 134 This later phenomenon is supported in a recent in vitro study of ischemic injury where the beneficial effects of deferoxamine in reducing hippocampal neuronal death were diminished in the presence of an antisense oligonucleotide specific for hypoxia-inducible factor-1alpha. 135 Deferoxamine has also been studied in vivo. After TBI in the adult rodent, deferoxamine treatment improves behavioral motor recovery by attenuating injury. 136, 137 It has also been shown to reduce brain edema 138 and improve motor recovery 136 -138 in experimental models of TBI 136, 137 and intracerebral hemorrhage. 138 Additionally, in large animal models of hypoxic/ischemic injury in the immature brain, deferoxamine reduces free iron levels, preserves cerebral energy metabolism and electrical brain activity, and attenuates edema. 139, 140 With such compelling evidence for the beneficial effects of iron chelation in varying types of brain injury, deferoxamine, or a similar compound, is a prime therapeutic candidate for the treatment of TBI in children.
CONCLUSION
Relative to adult TBI, our understanding of and ability to medically manage pediatric TBI is still in its infancy. We must begin by developing a better understanding of those factors that govern injury and repair processes in the context of brain maturation. Here we consider three specific therapeutic targets based upon what is currently known about the unique vulnerability of the developing brain to injury -inflammation, oxidative injury, and iron-mediated damage. Selective blockade of these pathobiologic events in the acutely injured brain may not only promote tissue sparing but may also define a wound healing environment that acts synergistically with developmental processes to restore function.
Several issues emerge from this review. First, there are likely to be pathobiologic events that are common to brain injury in both the adult and immature brain.
Nevertheless, successful targeting of these events in the adult brain may not be predictive of similar success in the immature brain where there may be broader developmental consequences. Thus, neurotherapeutic candidates should be stringently evaluated in the context of development. Second, although there is an ongoing effort to standardize and improve the clinical management of the brain-injured child, advances in targeted therapeutic interventions are limited in scope. Therefore, there is much to be gained by developing and characterizing novel agents in age-appropriate models of TBI. To expedite clinical trials, it is also important to consider therapeutic agents, such as deferoxamine, that are currently approved for use in humans and have the potential of reaching human trials and widespread use much more rapidly.
Finally, the pathogenesis of TBI should be considered in a more enduring context where aberrant tissue remodeling and disruption of normal developmental processes impede recovery. Thus, the long-term treatment of TBI should entail a multidisciplinary approach, where pharmacotherapy is merged with sensorimotor and cognitive neurorehabilitation to maximize recovery of function in the brain-injured child. 
